[ad_1]
last minute “data-mce-href =” https://www.ntv.com.tr/son-dakika “> Latest news! The American pharmaceutical giant Pfizer has developed the vaccine with the German BioNtech SE on over 43 thousand volunteers in 6 countries. Announced that it provides more than 95% protection in clinical trial results in the final phase.
SIDE EFFECTS OF LIGHT OBSERVED
“Bnt162b2” says the vaccine of November 13, July 27, USA, Germany, Turkey, South Africa, Brazil and Argentina in the third phase of clinical trials conducted on 43 thousand 661 people who attended. In the statement released by the company, it was reported that the vaccine gave stable results in all ages and ethnic groups and caused no significant side effects.
After administration of the first or second dose of the vaccine, 3.8% of the volunteers were reported to experience fatigue, 2% headaches, and after administration of the second dose, fever and mild side effects occurred. in elderly participants.
IMMUNITY IN 29 DAYS
However, vaccine efficacy has been reported to be 94% over the age of 65, who are at high risk from Covid-19. It was claimed that the vaccine provided the level of antibodies needed to inactivate the virus in 29 days.
However, the coronavirus vaccine application for emergency use in the United States is expected to occur within days. In the company’s previous statement, it was announced that the vaccine, which is expected to be given in two doses by the end of the year, will produce 50 million doses and 1.3 billion doses by the end of next year.
THE MOST EFFECTIVE VACCINE CURRENTLY AVAILABLE
Pfizer / Moderna announced last week that the vaccine it developed provided more than 90% protection in intermediate clinical data, then US pharmaceutical company Moderna announced that its own vaccine provided 94.5 protection. % the day before. Pfizer’s new announcement now makes it the company with the most potent potential vaccine on the market.
PROF. THE VACCINE DEVELOPER EXPLANATION BY ŞAHİN
Speaking to the Financial Times, the co-founder of BioNTech SE, prof. Dr Uğur Şahin said the vaccine had mild and moderate side effects due to its relatively low dose. Şahin said the messenger ribonucleic acid used to make the vaccine could create a “new class of drugs” (mRNA).
In the statement made by Şahin, “Our goal was to design and develop a vaccine that can be tolerated in all age groups from the start. We believe we have successfully achieved our goal in our vaccine candidate named BNT162b2. We are currently in contact with regulatory organizations to share the details of our work. Thanks to all the people who are committed to this historic success. We will continue to work in collaboration with our partners and governments for the distribution of the vaccine around the world “were use expressions.
INCREASE IN THE SHARE VALUE OF PFIZER AND BIONTECH
After the announcement, Pfizer’s shares were up 7%, while BioNTech’s shares traded in the United States were up 7.3%.
Source link
